search button
Open Access

Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

  • Authors:
    • Rongxin Liao
    • Peng Zhao
    • Jianming Wu
    • Keren Fang

  • View Affiliations

  • Published online on: January 5, 2023     https://doi.org/10.3892/etm.2023.11788
  • Article Number: 89

  • Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sepsis is a systemic inflammatory response syndrome, mainly caused by infection or suspected infectious factors. The intestine is not only one of the most easily involved organs in the course of sepsis, but also the dynamic organ for the course of sepsis. The present study investigated the protective effect and mechanism of salidroside on intestinal barrier dysfunction of septic mice. Briefly, C57BL/6 mice were used to establish a septic model and then administered with salidroside. The ileum tissues of mice were examined by histopathological examination. Fluorescein isothiocyanate‑dextran concentration was measured. IL‑17, IL‑6, IL‑13 and TNF‑α levels in ileum tissues and NF‑κB and p38 MAPK activations were detected by ELISA and the expressions of NF‑κB p65 and p38 MAPK protein with their phosphorylation and intestinal tight junction proteins were gauged by western blotting. The above assays were performed again to investigate the effect of anti‑IL‑17A and salidroside (160 mg/kg) alone or in combination. The septic model induced the ileum tissue injury, increased intestinal permeability and TNF‑α, IL‑17 and IL‑6 levels, activated NF‑κB and p38 MAPK pathways, promoted the expressions of NF‑κB p65 and p38 MAPK and their phosphorylation, while suppressing the levels of IL‑13 and intestinal tight junction proteins. Salidroside and anti‑IL‑17A partially reversed the above effects of septic model, which in combination further strengthened the reversing effect. Collectively, salidroside protected against intestinal barrier dysfunction in septic mice by downregulating IL‑17 level to inhibit NF‑κB and p38 MAPK signaling pathways, thus providing a new treatment direction.
View Figures
View References

Related Articles

Journal Cover

February-2023
Volume 25 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liao R, Zhao P, Wu J and Fang K: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways. Exp Ther Med 25: 89, 2023.
APA
Liao, R., Zhao, P., Wu, J., & Fang, K. (2023). Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways. Experimental and Therapeutic Medicine, 25, 89. https://doi.org/10.3892/etm.2023.11788
MLA
Liao, R., Zhao, P., Wu, J., Fang, K."Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways". Experimental and Therapeutic Medicine 25.2 (2023): 89.
Chicago
Liao, R., Zhao, P., Wu, J., Fang, K."Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways". Experimental and Therapeutic Medicine 25, no. 2 (2023): 89. https://doi.org/10.3892/etm.2023.11788